Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15004557 | 0.92 | CCNE1 (0.43) | FDPSCCNE1CDK2CDK5SLC6A3 | |
| SCHEMBL12844168 | 0.87 | — | — | |
| SCHEMBL18673935 | 0.84 | SLC6A3 (0.43) | FDPSSLC6A3HCAR2ALDH1A1MEN1 | |
| SCHEMBL11561896 | 0.82 | POLB (0.39) | FDPSCCNE1CDK2CDK5SLC6A3 | |
| SCHEMBL11561789 | 0.82 | SLC6A3 (0.37) | FDPSSLC6A3HCAR2HRH3ALDH1A1 | |
| SCHEMBL2090265 | 0.82 | SLC6A3 (0.37) | FDPSSLC6A3HCAR2ALDH1A1MEN1 | |
| SCHEMBL34463069 | 0.81 | — | — | |
| SCHEMBL2096690 | 0.80 | SLC6A3 (0.36) | FDPSCCNE1CDK2CDK5SLC6A3 | |
| SCHEMBL14045404 | 0.79 | FDPS (0.50) | FDPSCCNE1CDK2CDK5SLC6A3 | |
| SCHEMBL2089954 | 0.79 | SLC6A3 (0.36) | FDPSCCNE1CDK2CDK5SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480247-B1 | NOVEL NPR-B AGONISTS | SHIRE ORPHAN THERAPIES GMBH (DE) | 2020-02-12 | — | — | EP | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160194357-A1 | Novel NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9187525-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9169293-B2 | NPR-B agonists | Shire Orphan Thereapies GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-8551938-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8546523-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100240890-A1 | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL IND. CO., LTD. | 2010-09-23 | — | — | US | disclosed |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | PFIZER LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313743-A1 | NPR-B Agonists | NPR1, NPR3, NPBWR1 | FDPS 2539/4885CCNE1 4728/4885CDK2 4353/4885 |
| US-20160194357-A1 | Novel NPR-B Agonists | NPR1, NPR3, NPBWR1 | FDPS 3001/4885CCNE1 4696/4885CDK2 4325/4885 |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | ADRB2, ADRB1, ADRA2C | FDPS 3957/4885CCNE1 3248/4885CDK2 1805/4885 |
| US-20100240890-A1 | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | CMA1, IL5, HRH4 | FDPS 1669/4885CCNE1 3326/4885CDK2 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.